Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5OTHER_GOV 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 196Neoplasms 104Colorectal Neoplasms 91Stomach Neoplasms 80Uterine Cervical Neoplasms 71Carcinoma, Non-Small-Cell Lung 67Carcinoma, Hepatocellular 54Prostatic Neoplasms 48Lung Neoplasms 48Rectal Neoplasms 46Esophageal Neoplasms 39Pancreatic Neoplasms 37Colonic Neoplasms 36Ovarian Neoplasms 35Recurrence 33Head and Neck Neoplasms 33Neoplasm Metastasis 28Motor Activity 28Multiple Myeloma 27Small Cell Lung Carcinoma 26Melanoma 25Polycystic Ovary Syndrome 24Lymphoma, Non-Hodgkin 24Lymphoma 24Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Pain 20Brain Neoplasms 20Nasopharyngeal Carcinoma 18Hematologic Neoplasms 17

Interventions

tislelizumab 2Oxaliplatin 2apatinib 1Tegafur 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Immunotherapy × Clear all
NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Immunotherapy

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Not yet recruiting
94 enrolled

Immunotherapy

NCT03619954 2018-08-08

NK Cells Infusion for Advanced Malignancies

Anhui Provincial Hospital

Phase 1 Unknown
50 enrolled

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡